Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q37875062

about

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy.Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

P2860

Q26823762-670F5D5D-E861-4613-A7D9-0F8E650BFE12 Q34632828-4083B5DB-D8D8-41A6-BDC6-E1DCCE1F5E30 Q38051005-F13F9A89-4ACF-4357-8059-4EC330480D91 Q38077543-288C083C-3A9C-499C-B2BD-C3AE9CECE89D Q38081486-2EE9B123-5FCB-4364-9B58-B80C9A50E732 Q38313282-70D973A5-16A3-4EE7-82F9-1A7887731D2A Q38364582-78FA38E7-5E3E-4695-99F4-03061EC38861 Q47434739-1221A23B-9BE2-4901-B32E-86B1DBAB65D6

P2860

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q37875062

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@en

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@nl

type

label

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@en

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@nl

prefLabel

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@en

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@nl

P1433

Q37875062-B390AC23-F001-4F5D-81E1-723BAB90D54E

P1476

Q37875062-1C2BB76D-586C-4C70-802C-2D585FBF030A

P2093

Q37875062-499A516F-74EC-43B6-9A9D-0AFA0F7F2D2B

P2860

Q37875062-0C9CCCC0-E69E-4416-B6FA-382DBEFB9E8B

Q37875062-17D6AA03-9231-46DF-AB5D-74D533E11C4E

Q37875062-2786A09B-FCDA-44B5-9CD9-35AF8A0EDDF7

Q37875062-3F28C6D8-C372-4AE5-BB45-6C14A6B83C37

Q37875062-47918B9E-EAB5-4EB0-965D-6676968BFE2D

Q37875062-5217FBA8-243F-468D-9EA5-501BD058E279

Q37875062-5570EAAB-85E4-42E8-A7E3-FE858CA3ECE6

Q37875062-658270F4-BDA1-46A7-99EC-799A9E595E17

Q37875062-730E7E7E-097E-4814-AD2B-8090B7D74D01

Q37875062-A6E1A5AA-DD09-49CC-81A7-78D5B41E905A

P2888

Q37875062-338EC2EF-2481-4A6A-BCDF-CB2E746108A5

P304

Q37875062-689B3F85-D5D3-4C84-AF04-A1EC76766ED0

P31

Q37875062-CA5E9DF0-37ED-446C-9F76-99C3C39EAF16

P356

Q37875062-7261600F-6A1A-4AEE-81C9-E7449E0C3927

P433

Q37875062-308A9C5D-CA3A-4BAC-A8E6-15AA50CFF567

P478

Q37875062-ED05E4D0-53FA-4091-A63E-8D5ED33007E0

P577

Q37875062-33D1B937-2FD6-4063-AB2C-84BCEBB14873

P6179

Q37875062-2BBA3E10-D3FA-45E7-8D61-7B64A0527849

P698

Q37875062-12EE0ABC-80FC-4EE6-9225-9660096684F7

P356

11204780-000000000-00000

P1433

P1476

Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

@en

P2093

Monique P Curran

http://www.w3.org/2001/XMLSchema#string

P2860

Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.

Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.

Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers.

Impact of dry ejaculation caused by highly selective alpha1A-blocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men.

Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.

Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.

Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

P2888

11204780-000000000-00000

P304

897-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11204780-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1051064911

http://www.w3.org/2001/XMLSchema#string

P698

21568366

http://www.w3.org/2001/XMLSchema#string